Lung cancer is among most common types of cancers in U.S. as well as around the world. According to the Centers for Disease Control and Prevention, it is responsible for nearly a quarter of U.S. cancer deaths in the year 2020. According to the new trial findings, taking Tagrisso, also known as Osimertinib, a once-daily medication, after removal of tumor via surgery reduces risk of people dying from cancer by 51%. The research is published recently in The New England Journal of Medicine.
In the trial, 682 patients were included with the mutation called T790M. About half of them took Osimertinib once a day while others took a placebo bill. These participants had surgically removed tumor and their cancers were at stage 1 2 or 3. Some of them had also completed chemotherapy treatments. The patients took the medicine and they were monitored for a median of five years. After the time period of five years 88% of those patients with Osimertinib remained alive as compared with 78% of the control population. This implies that the drug halved the risk of death during that five-year span. Also, the medicine was also to reduce disease recurrence as well. The patients in trial with more advanced level of cancer, 85% of those on Osimertinib survived after five years in comparison with 67% of those who took placebo.
This new study has shown evidence that same drug can improve outcomes along lung cancer patients with earlier stages. Deputy director of the Yale Cancer Center and lead author of the paper, Roy Herbst, said, “It’s really taking personalized therapy from advanced metastatic disease and moving it all the way to the earliest stages of lung cancer treatment.”
The information shared in this blog is for educational purposes only. You should always consult your healthcare practitioner for any medical needs.